Pushing new synbio frontiers in San Jose!
Hi there,
We can’t wait to attend SynBioBeta next month, joining industry and sector experts, policymakers, investors and other stakeholders at the premier gathering of the global synthetic biology community.
As the UK develops its position as a leader in synthetic biology, our CEO Mark Kotter takes stock of our engagement in several recent government synbio policy announcements in his latest blog. Read the article to learn how we are pushing the frontiers!
What's new?
Join us at SynBioBeta in San Jose
Early next month we're excited to participate in the global SynBioBeta conference in San Jose, helping shape a future crafted by synthetic biology. SynBioBeta is our premier industry gathering with three days of presentations, panel discussions, interviews and networking events. bit.bio will be participating in three panel discussions, including a main stage fireside chat between our CEO & Founder Mark Kotter and the cell programming pioneer, and Nobel Laureate, Thomas Südhof. For those lucky enough to be attending the conference, please visit our booth #301 in the Exhibit Hall.
Policy engagement to drive UK forward in synthetic biology
Recent months have seen several important announcements on the UK's ambitions to extend its leadership position in engineering biology. In our CEO's latest blog, Mark Kotter takes stock of key initiatives in which bit.bio has been actively engaged, such as the launch of the Government’s National Vision for Engineering Biology, as well as our fantastic new collaboration with The Michael J. Fox Foundation to accelerate the fight against Parkinson's disease.
Expert Insights
Watch one of our phenotyping experts present our latest data on ioMotor Neurons?
Poster sessions have an important role in the scientific community by facilitating networking and knowledge exchange. You can now watch our recent scientific poster presentation at the MaxWell Biosystems Summit 2024 on demand! Luke Foulser, one of our phenotyping experts, dives into the characterisation and electrophysiological functionality of our ioMotor Neurons.
Available now: World's first CRISPR-ready ioMicroglia? cuts functional genomic timelines from years to weeks
This month early-access testers got their hands on our first vials of CRISPR-ready ioMicroglia. Scientists on the hunt for new druggable targets for neuroinflammatory diseases like Alzheimer’s can access human male iPSC donor-derived microglia with a constitutively expressed Cas9 for the first time.
These cells allow for the easy generation of gene knockouts and CRISPR screens in a matter of weeks, avoiding the often year-long engineering and characterisation cycle required to generate iPSC-derived microglia with stable Cas9 expression. Explore the cells, and data on their use in a knockout screen on our scientific poster.
领英推荐
Upcoming Events
May 6 - 9
San Jose | USA
SynBioBeta
Join us at an unparalleled summit delving into synthetic biology. Meet our team to discover what is different about cell programming and how we are combining technology and biology to accelerate a new generation of medicines.
May 9
London | UK
Lazard T500 Venture & Growth Conference
We are looking forward to the Lazard T500 conference, bringing together the most promising private European venture and growth companies with a network of leading global venture and growth investors and other vital contributors to the Venture & Growth ecosystem.
ARRANGE A MEETING > [email protected]
May 12 - 14
San Sebastian | Spain
24th Annual Bio€quity Europe
Join us at the 24th Annual Bio€quity Europe conference, Europe’s premier international showcase for investors, financial dealmakers and biopharma executives to meet rising biotechs. Don’t wait to book your ticket to San Sebastian, one of the culinary capitals of the world!
Explore the full list of events we are attending here.